Charles River Laboratories (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2013 | 06-2013 | 03-2013 | 12-2012 | 09-2012 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 130,454 | 113,521 | 100,422 | 109,685 | 83,224 |
| Receivables | 224,270 | 224,030 | 213,540 | 203,001 | 215,621 |
| Inventories | 87,146 | 88,405 | 84,959 | 88,470 | 93,718 |
| Other current assets | 105,911 | 93,801 | 93,698 | 84,096 | 65,352 |
| TOTAL | $547,781 | $519,757 | $492,619 | $485,252 | $457,915 |
| Non-Current Assets | |||||
| PPE Net | 690,725 | 696,495 | 707,053 | 717,020 | 724,699 |
| Intangibles | 316,516 | 317,734 | 322,117 | 293,531 | 297,197 |
| Other Non-Current Assets | 88,745 | 87,612 | 82,019 | 90,541 | 87,807 |
| TOTAL | $1,095,986 | $1,101,841 | $1,111,189 | $1,101,092 | $1,109,703 |
| Total Assets | $1,643,767 | $1,621,598 | $1,603,808 | $1,586,344 | $1,567,618 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 16,170 | 16,163 | 130,851 | 139,384 | 125,603 |
| Accounts payable and accrued liabilities | 29,675 | 37,295 | 31,277 | 31,218 | 27,744 |
| Accrued Expenses | 111,412 | 93,864 | 91,698 | 92,159 | 98,426 |
| Other current liabilities | 20,613 | 22,557 | 21,166 | 21,262 | 14,539 |
| TOTAL | $235,171 | $225,854 | $330,812 | $342,247 | $325,237 |
| Non-Current Liabilities | |||||
| Long Term Debt | 624,310 | 619,771 | 518,035 | 527,136 | 543,143 |
| Deferred Revenues | 55,357 | 53,695 | 53,187 | 56,422 | 57,833 |
| Other Non-Current Liabilities | 124,476 | 124,830 | 123,940 | 113,649 | 99,056 |
| TOTAL | $749,142 | $745,030 | $642,168 | $640,897 | $642,429 |
| Total Liabilities | $984,313 | $970,884 | $972,980 | $983,144 | $967,666 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 48,118 | 49,061 | 49,029 | 48,182 | 48,553 |
| Common Shares | 817 | 810 | 807 | 796 | 794 |
| Retained earnings | -284,572 | -315,439 | -342,723 | -368,301 | -386,717 |
| Other shareholders' equity | 1,308 | -16,711 | -10,522 | 9,389 | 17,841 |
| TOTAL | $659,454 | $650,714 | $630,828 | $603,200 | $599,952 |
| Total Liabilities And Equity | $1,643,767 | $1,621,598 | $1,603,808 | $1,586,344 | $1,567,618 |